Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Radiation Dosimetry of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer
Latest Information Update: 06 Oct 2023
At a glance
- Drugs HRS-9815 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 06 Oct 2023 New trial record